Elevated pre-treatment NLR was significantly associated with worse OS in 81 advanced EGFR-mutated NSCLC patients treated with first-line EGFR TKIs [28], as well as in 199 never smokers with advanced NSCLC receiving gefitinib or standard chemotherapy [29]. Here, EGFR is linked to non-small cell lung carcinoma.